

May 2, 2016



CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11

NEWARK, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Wednesday, May 11th at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2016.

Conference Call Details

To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, and use Conference ID # 13636131.

To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at <http://ir.cymbay.com/events>.

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPAR δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed a pilot Phase 2 study of MBX-8025 in patients with homozygous familial hypercholesterolemia and has an ongoing Phase 2 study in patients with primary biliary cholangitis. Arhalofenate, CymaBay's other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.

For additional information about CymaBay visit www.cymbay.com.

Contact:

Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
Investors@CymaBay.com

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com



Source: CymaBay Therapeutics, Inc.